NEUROCRINE BIOSCIENCES INC Income Taxes Paid
NEUROCRINE BIOSCIENCES INC (NBIX) reported Income Taxes Paid of $88.20 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:IncomeTaxesPaid · last filed 2026-07-31
- NEUROCRINE BIOSCIENCES INC income taxes paid for the quarter ending 2026-06-30 was $87.90M, a 22.25% increase year-over-year.
- NEUROCRINE BIOSCIENCES INC income taxes paid for the quarter ending 2026-03-31 was $300.00K, a 50.00% decline year-over-year.
- NEUROCRINE BIOSCIENCES INC income taxes paid for the quarter ending 2025-12-31 was $7.80M, a 89.32% decline year-over-year.
- NEUROCRINE BIOSCIENCES INC income taxes paid for the quarter ending 2025-09-30 was $1.10M, a 97.87% decline year-over-year.
- NEUROCRINE BIOSCIENCES INC income taxes paid for fiscal 2025 was $81.40M, a 62.57% decline from fiscal 2024.
- NEUROCRINE BIOSCIENCES INC income taxes paid for fiscal 2024 was $217.50M, a 322.33% increase from fiscal 2023.
- NEUROCRINE BIOSCIENCES INC income taxes paid for fiscal 2023 was $51.50M, a 257.64% increase from fiscal 2022.
- NEUROCRINE BIOSCIENCES INC income taxes paid for fiscal 2022 was $14.40M, a 182.35% increase from fiscal 2021.
| Period end | Income Taxes Paid 3 month | Income Taxes Paid 6 month | Income Taxes Paid 9 month | Income Taxes Paid 12 month | Income Taxes Paid 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $87.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-31 | $88.20M 10-Q · filed 2026-07-31 | $96.00M derived: sum of 3 quarters · filed 2026-07-31 | $97.10M derived: sum of 4 quarters · filed 2026-07-31 | |
| 2026-03-31 | $300.00K 10-Q · filed 2026-05-05 | $8.10M derived: sum of 2 quarters · filed 2026-05-05 | $9.20M derived: sum of 3 quarters · filed 2026-05-05 | $81.10M derived: sum of 4 quarters · filed 2026-07-31 | |
| 2025-12-31 | $7.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $8.90M derived: sum of 2 quarters · filed 2026-02-11 | $80.80M derived: sum of 3 quarters · filed 2026-07-31 | $81.40M 10-K · filed 2026-02-11 | |
| 2025-09-30 | $1.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $73.00M derived: sum of 2 quarters · filed 2026-07-31 | $73.60M 10-Q · filed 2025-10-28 | $146.60M derived: sum of 4 quarters · filed 2026-07-31 | |
| 2025-06-30 | $71.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-31 | $72.50M 10-Q · filed 2026-07-31 | $145.50M derived: sum of 3 quarters · filed 2026-07-31 | $197.20M derived: sum of 4 quarters · filed 2026-07-31 | |
| 2025-03-31 | $600.00K 10-Q · filed 2026-05-05 | $73.60M derived: sum of 2 quarters · filed 2026-05-05 | $125.30M derived: sum of 3 quarters · filed 2026-05-05 | $217.90M derived: sum of 4 quarters · filed 2026-05-05 | |
| 2024-12-31 | $73.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $124.70M derived: sum of 2 quarters · filed 2026-02-11 | $217.30M derived: sum of 3 quarters · filed 2026-02-11 | $217.50M 10-K · filed 2026-02-11 | |
| 2024-09-30 | $51.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $144.30M derived: sum of 2 quarters · filed 2025-10-28 | $144.50M 10-Q · filed 2025-10-28 | $191.00M derived: sum of 4 quarters · filed 2026-02-11 | |
| 2024-06-30 | $92.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-30 | $92.80M 10-Q · filed 2025-07-30 | $139.30M derived: sum of 3 quarters · filed 2026-02-11 | $140.90M derived: sum of 4 quarters · filed 2026-02-11 | |
| 2024-03-31 | $200.00K 10-Q · filed 2025-05-05 | $46.70M derived: sum of 2 quarters · filed 2026-02-11 | $48.30M derived: sum of 3 quarters · filed 2026-02-11 | $51.50M derived: sum of 4 quarters · filed 2026-02-11 | |
| 2023-12-31 | $46.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $48.10M derived: sum of 2 quarters · filed 2026-02-11 | $51.30M derived: sum of 3 quarters · filed 2026-02-11 | $51.50M 10-K · filed 2026-02-11 | |
| 2023-09-30 | $1.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | $4.80M derived: sum of 2 quarters · filed 2024-10-30 | $5.00M 10-Q · filed 2024-10-30 | $15.10M derived: sum of 4 quarters · filed 2025-02-10 | |
| 2023-06-30 | $3.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $3.40M 10-Q · filed 2024-08-01 | $13.50M derived: sum of 3 quarters · filed 2025-02-10 | $14.70M derived: sum of 4 quarters · filed 2025-02-10 | |
| 2023-03-31 | $200.00K 10-Q · filed 2024-05-01 | $10.30M derived: sum of 2 quarters · filed 2025-02-10 | $11.50M derived: sum of 3 quarters · filed 2025-02-10 | $14.60M derived: sum of 4 quarters · filed 2025-02-10 | |
| 2022-12-31 | $10.10M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-10 | $11.30M derived: sum of 2 quarters · filed 2025-02-10 | $14.40M derived: sum of 3 quarters · filed 2025-02-10 | $14.40M 10-K · filed 2025-02-10 | |
| 2022-09-30 | $1.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-31 | $4.30M derived: sum of 2 quarters · filed 2023-10-31 | $4.30M 10-Q · filed 2023-10-31 | $6.00M derived: sum of 4 quarters · filed 2024-02-09 | |
| 2022-06-30 | $3.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-01 | $3.10M 10-Q · filed 2023-08-01 | $4.80M derived: sum of 3 quarters · filed 2024-02-09 | $6.60M derived: sum of 4 quarters · filed 2024-02-09 | |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-03 | $1.70M derived: sum of 2 quarters · filed 2024-02-09 | $3.50M derived: sum of 3 quarters · filed 2024-02-09 | ||
| 2021-12-31 | $1.70M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-09 | $3.50M derived: sum of 2 quarters · filed 2024-02-09 | $5.10M 10-K · filed 2024-02-09 | ||
| 2021-09-30 | $1.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | $3.40M 10-Q · filed 2022-11-01 | |||
| 2021-06-30 | $1.60M 10-Q · filed 2022-08-04 | ||||
| 2020-12-31 | $14.90M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-09 | $15.30M derived: sum of 2 quarters · filed 2023-02-09 | $15.30M 10-K · filed 2023-02-09 | ||
| 2020-09-30 | $400.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-01 | $400.00K 10-Q · filed 2021-11-01 | |||
| 2020-06-30 | $0.00 10-Q · filed 2021-08-03 | ||||
| 2019-12-31 | -$7.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-11 | $75.00K derived: sum of 2 quarters · filed 2022-02-11 | $500.00K 10-K · filed 2022-02-11 | $507.00K 10-K · filed 2020-02-07 | |
| 2019-09-30 | $82.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-04 | $507.00K 10-Q · filed 2019-11-04 | |||
| 2019-06-30 | $425.00K 10-Q · filed 2019-07-29 | ||||
| 2018-12-31 | $0.00 10-K · filed 2021-02-05 | ||||
| 2017-12-31 | $0.00 10-K · filed 2020-02-07 | ||||
| 2016-12-31 | $0.00 10-K · filed 2018-02-13 | ||||
| 2015-12-31 | $0.00 10-K · filed 2018-02-13 | ||||
| 2014-12-31 | $0.00 10-K · filed 2017-02-14 | ||||
| 2013-12-31 | $0.00 10-K · filed 2016-02-11 | ||||
| 2012-12-31 | $0.00 10-K · filed 2015-02-09 | ||||
| 2011-12-31 | $0.00 10-K · filed 2014-02-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |